Ingenuity canonical pathways | Complete | pQTL | Proteins with pQTL in italic | ||
---|---|---|---|---|---|
Regulated | Scorea | Regulated | Scorea | ||
Mitochondrial dysfunction | 9/171 (5%) | 7.22 | 7/171 (4%) | 6.18 | PDHA1, PRDX3, NDUFS1, SOD2, ATP5B, PARK7, GPX4, VDAC1, NDUFS3 |
Gluconeogenesis I | 4/25 (16%) | 5.40 | 4/25 (16%) | 6.10 | ENO1, PGAM1, ME1, MDH1 |
NRF2-mediated oxidative stress response | 7/180 (4%) | 4.85 | 6/180 (3%) | 4.84 | AKR1A1, SOD2, PRDX1, ACTB, VCP, CCT7, ACTG1 |
Glycolysis I | 3/25 (12%) | 3.76 | 3/25 (12%) | 4.28 | ENO1, TPI1, PGAM1 |
Acetyl-CoA biosynthesis I | 3/7 (43%) | 5.56 | 2/7 (29%) | 3.76 | PDHA1, DLAT, PDHB |
LXR/RXR activation | 5/121 (4%) | 3.72 | 4/121 (3%) | 3.36 | TTR, ALB, APOA1, TF, FASN |
FXR/RXR activation | 5/126 (4%) | 3.64 | 4/126 (3%) | 3.29 | Â |
Caveolar-mediated endocytosis signaling | 3/71 (4%) | 2.43 | 3/71 (4%) | 2.93 | ALB, ACTB, ACTG1 |
Acute phase response signaling | 5/169 (3%) | 3.06 | 4/169 (2%) | 2.82 | TTR, ALB, SOD2, APOA1, TF |
TR/RXR activation | 3/85 (4%) | 2.21 | 3/85 (4%) | 2.70 | ENO1, FASN, ME1 |
Tryptophan degradation X | 4/23 (17%) | 5.55 | 2/23 (9%) | 2.69 | ALDH2, AKR1A1, ALDH9A1, ALDH7A1 |
Ethanol degradation II | 4/35 (11%) | 4.79 | 2/35 (6%) | 2.33 | Â |
Noradrenaline and adrenaline degradation | 4/38 (11%) | 4.65 | 2/38 (5%) | 2.26 | Â |
Clathrin-mediated Endocytosis signaling | 5/185 (3%) | 2.88 | 4/185 (2%) | 2.67 | ALB, APOA1, TF, ACTB, ACTG1 |